Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

SHPH

Shuttle Pharmaceuticals (SHPH)

Shuttle Pharmaceuticals Holdings Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SHPH
FechaHoraFuenteTítuloSímboloCompañía
18/06/202408:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
18/06/202408:00GlobeNewswire Inc.Shuttle Pharma Appoints Timothy Lorber as Chief Financial OfficerNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
10/06/202405:12Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
22/05/202415:15GlobeNewswire Inc.Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
14/05/202408:00GlobeNewswire Inc.Shuttle Pharma Provides First Quarter 2024 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/05/202416:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
23/04/202415:15GlobeNewswire Inc.Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
22/03/202408:00PR Newswire (US)Shuttle Pharma Provides Fourth Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
08/03/202417:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/02/202407:00PR Newswire (US)Shuttle Pharma Announces Its Intent to Pursue a Rights OfferingNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
23/01/202415:30PR Newswire (US)Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
08/01/202408:00PR Newswire (US)Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
11/12/202308:00PR Newswire (US)Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
14/11/202308:00PR Newswire (US)Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
31/10/202308:00PR Newswire (US)Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License AgreementNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
20/10/202315:15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
20/10/202315:10Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
10/10/202308:00PR Newswire (US)Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor ConferenceNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
25/09/202308:00PR Newswire (US)Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/09/202308:00PR Newswire (US)Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health FairNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
11/09/202308:00PR Newswire (US)Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor PlatformNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
29/08/202308:00PR Newswire (US)Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer TherapeuticsNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
24/08/202313:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
15/08/202308:00PR Newswire (US)Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
03/08/202308:00PR Newswire (US)Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical TrialNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
16/06/202305:31Edgar (US Regulatory)Information Statement - All Other (definitive) (def 14c)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
05/06/202315:29Edgar (US Regulatory)Proxy Statement - Other Information (preliminary) (pre 14c)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
30/05/202316:31Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
26/05/202308:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
26/05/202308:00PR Newswire (US)Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:SHPH

Su Consulta Reciente

Delayed Upgrade Clock